Investigational drugs in clinical trials for Hidradenitis Suppurativa

References

• Jemec GB. Clinical practice. Hidradenitis suppurativa. N Engl J Med. 2012;366:158–164.
   PubMed Web of Science ®Google Scholar
• Saunte DM, Boer J, Stratigos A, et al. Diagnostic delay in hidradenitis suppurativa is a global problem. Br J Dermatol. 2015;173:1546–1549.
   PubMed Web of Science ®Google Scholar
• Ingram JR, Woo PN, Chua SL, et al. Interventions for hidradenitis suppurativa: a Cochrane systematic review incorporating GRADE assessment of evidence quality. Br J Dermatol. 2016;174:970–978.
   PubMed Web of Science ®Google Scholar
• Zouboulis CC, Desai N, Emtestam L, et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol. 2015;29:619–644.
   PubMed Web of Science ®Google Scholar
• Zouboulis CC, Del Marmol V, Mrowietz U, et al. Hidradenitis suppurativa/acne inversa: criteria for diagnosis, severity assessment, classification and disease evaluation. Dermatology. 2015;231:184–190.
   PubMed Web of Science ®Google Scholar
• Hurley H. Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa, and familial benign pemphigus: surgical approach. Dermatologic Surgery. 1989;729–739.
   Google Scholar
• Kromann CB, Deckers IE, Esmann S, et al. Risk factors, clinical course and long-term prognosis in hidradenitis suppurativa: a cross-sectional study. Br J Dermatol. 2014;171:819–824.
   PubMed Web of Science ®Google Scholar
• Busch K, Ludvigsson JF, Ekstrom-Smedby K, et al. Nationwide prevalence of inflammatory bowel disease in Sweden: a population-based register study. Aliment Pharmacol Ther. 2014;39:57–68.
   PubMed Web of Science ®Google Scholar
• Pedersen OB, Svendsen AJ, Ejstrup L, et al. The occurrence of psoriatic arthritis in Denmark. Ann Rheum Dis. 2008;67:1422–1426.
   PubMed Web of Science ®Google Scholar
• Parisi R, Symmons DP, Griffiths CE, et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133:377–385.
   PubMed Web of Science ®Google Scholar
• Kouris A, Platsidaki E, Christodoulou C, et al. Quality of life and psychosocial implications in patients with hidradenitis Suppurativa. Dermatology. 2016;232:687–691.
   PubMed Web of Science ®Google Scholar
• Miller IM, McAndrew RJ, Hamzavi I. Prevalence, risk factors, and comorbidities of hidradenitis Suppurativa. Dermatol Clin. 2016;34:7–16.
   PubMed Web of Science ®Google Scholar
• Shavit E, Dreiher J, Freud T, et al. Psychiatric comorbidities in 3207 patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2015;29:371–376.
   PubMed Web of Science ®Google Scholar
• Egeberg A, Gislason GH, Hansen PR. Risk of major adverse cardiovascular events and all-cause mortality in patients with hidradenitis Suppurativa. JAMA Dermatol. 2016;152(4):429–434.
   Web of Science ®Google Scholar
• Jemec GB. Quality of life considerations and pain management in hidradenitis suppurativa. Semin Cutan Med Surg. 2017;36:75–78.
   PubMed Web of Science ®Google Scholar
• Esmann S, Jemec GB. Psychosocial impact of hidradenitis suppurativa: a qualitative study. Acta Derm Venereol. 2011;91:328–332.
   PubMed Web of Science ®Google Scholar
• Dalgard FJ, Gieler U, Tomas-Aragones L, et al. The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries. J Invest Dermatol. 2015;135:984–991.
   PubMed Web of Science ®Google Scholar
• Vazquez BG, Alikhan A, Weaver AL, et al. Incidence of hidradenitis suppurativa and associated factors: a population-based study of Olmsted County, Minnesota. J Invest Dermatol. 2013;133:97–103.
   PubMed Web of Science ®Google Scholar
• Deckers IE, Kimball AB. The handicap of hidradenitis suppurativa. Dermatol Clin. 2016;34:17–22.
   PubMed Web of Science ®Google Scholar
• Gold DA, Reeder VJ, Mahan MG, et al. The prevalence of metabolic syndrome in patients with hidradenitis suppurativa. J Am Acad Dermatol. 2014;70:699–703.
   PubMed Web of Science ®Google Scholar
• Miller IM, Ellervik C, Vinding GR, et al. Association of metabolic syndrome and hidradenitis suppurativa. JAMA Dermatol. 2014;150:1273–1280.
   PubMed Web of Science ®Google Scholar
• Shalom G, Freud T, Harman-Boehm I, et al. Hidradenitis suppurativa and metabolic syndrome: a comparative cross-sectional study of 3207 patients. Br J Dermatol. 2015;173:464–470.
   PubMed Web of Science ®Google Scholar
• Hu W, Wu XJ, Ni YJ, et al. Metabolic syndrome is independently associated with a mildly reduced estimated glomerular filtration rate: a cross-sectional study. BMC Nephrol. 2017;18:192.
   PubMed Web of Science ®Google Scholar
• Guh DP, Zhang W, Bansback N, et al. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health. 2009;9:88.
   PubMed Web of Science ®Google Scholar
• van der Zee HH, de Winter K, van der Woude CJ, et al. The prevalence of hidradenitis suppurativa in 1093 patients with inflammatory bowel disease. Br J Dermatol. 2014;171:673–675.
   PubMed Web of Science ®Google Scholar
• Shlyankevich J, Chen AJ, Kim GE, et al. Hidradenitis suppurativa is a systemic disease with substantial comorbidity burden: a chart-verified case-control analysis. J Am Acad Dermatol. 2014;71:1144–1150.
   PubMed Web of Science ®Google Scholar
• Menter A. Recognizing and managing comorbidities and complications in hidradenitis suppurativa. Semin Cutan Med Surg. 2014;33:S54–6.
   PubMed Web of Science ®Google Scholar
• Alikhan A, Lynch PJ, Eisen DB. Hidradenitis suppurativa: a comprehensive review. J Am Acad Dermatol. 2009;60: 539–561. quiz 62-3.
   PubMed Web of Science ®Google Scholar
• Chicarilli ZN. Follicular occlusion triad: hidradenitis suppurativa, acne conglobata, and dissecting cellulitis of the scalp. Ann Plast Surg. 1987;18:230–237.
   PubMed Web of Science ®Google Scholar
• Scheinfeld NS. A case of dissecting cellulitis and a review of the literature. Dermatol Online J. 2003;9:8.
   PubMedGoogle Scholar
• Balieva F, Kupfer J, Lien L, et al. The burden of common skin diseases assessed with the EQ5D: a European multicentre study in 13 countries. Br J Dermatol. 2017;176:1170–1178.
   PubMed Web of Science ®Google Scholar
• Jemec GB, Heidenheim M, Nielsen NH. Hidradenitis suppurativa–characteristics and consequences. Clin Exp Dermatol. 1996;21:419–423.
   PubMed Web of Science ®Google Scholar
• Theut Riis P, Thorlacius L, Knudsen List E, et al. A pilot study of unemployment in patients with hidradenitis suppurativa in Denmark. Br J Dermatol. 2017;176:1083–1085.
   PubMed Web of Science ®Google Scholar
• Deckers IE, Janse IC, van der Zee HH, et al. Hidradenitis suppurativa (HS) is associated with low socioeconomic status (SES): a cross-sectional reference study. J Am Acad Dermatol. 2016;75(4):755–759.e1.
   Google Scholar
• von Laffert M, Stadie V, Wohlrab J, et al. Hidradenitis suppurativa/acne inversa: bilocated epithelial hyperplasia with very different sequelae. Br J Dermatol. 2011;164:367–371.
   PubMed Web of Science ®Google Scholar
• von Laffert M, Helmbold P, Wohlrab J, et al. Hidradenitis suppurativa (acne inversa): early inflammatory events at terminal follicles and at interfollicular epidermis. Exp Dermatol. 2010;19:533–537.
   PubMed Web of Science ®Google Scholar
• Jemec GB, Thomsen BM, Hansen U. The homogeneity of hidradenitis suppurativa lesions. A histological study of intra-individual variation. APMIS. 1997;105:378–383.
   PubMed Web of Science ®Google Scholar
• Jemec GB, Hansen U. Histology of hidradenitis suppurativa. J Am Acad Dermatol. 1996;34:994–999.
   PubMed Web of Science ®Google Scholar
• Yu CC, Cook MG. Hidradenitis suppurativa: a disease of follicular epithelium, rather than apocrine glands. Br J Dermatol. 1990;122:763–769.
   PubMed Web of Science ®Google Scholar
• van der Zee HH, de Ruiter L, Boer J, et al. Alterations in leucocyte subsets and histomorphology in normal-appearing perilesional skin and early and chronic hidradenitis suppurativa lesions. Br J Dermatol. 2012;166:98–106.
   PubMed Web of Science ®Google Scholar
• Nikolakis G, Join-Lambert O, Karagiannidis I, et al. Bacteriology of hidradenitis suppurativa/acne inversa: a review. J Am Acad Dermatol. 2015;73:S12–8.
   PubMed Web of Science ®Google Scholar
• Ring HC, Emtestam L. The microbiology of Hidradenitis Suppurativa. Dermatol Clin. 2016;34:29–35.
   PubMed Web of Science ®Google Scholar
• Ring HC, Riis Mikkelsen P, Miller IM, et al. The bacteriology of hidradenitis suppurativa: a systematic review. Exp Dermatol. 2015;24:727–731.
   PubMed Web of Science ®Google Scholar
• Ring HC, Bay L, Kallenbach K, et al. Normal skin microbiota is altered in pre-clinical Hidradenitis Suppurativa. Acta Derm Venereol. 2017;97:208–213.
   PubMed Web of Science ®Google Scholar
• Ring HC, Thorsen J, Saunte DM, et al. The follicular skin microbiome in patients with Hidradenitis Suppurativa and healthy controls. JAMA Dermatol. 2017;153:897–905.
   PubMed Web of Science ®Google Scholar
• Miller IM, Ring HC, Prens EP, et al. Leukocyte profile in peripheral blood and neutrophil-lymphocyte ratio in Hidradenitis Suppurativa: a comparative cross-sectional study of 462 cases. Dermatology. 2016.
   PubMedGoogle Scholar
• Riis PT, Soeby K, Saunte DM, et al. Patients with hidradenitis suppurativa carry a higher systemic inflammatory load than other dermatological patients. Arch Dermatol Res. 2015;307:885–889.
   PubMed Web of Science ®Google Scholar
• Kanni T, Tzanetakou V, Savva A, et al. Compartmentalized cytokine responses in Hidradenitis Suppurativa. PLoS One. 2015;10:e0130522.
   PubMed Web of Science ®Google Scholar
• Montaudie H, Seitz-Polski B, Cornille A, et al. Interleukin 6 and high-sensitivity C-reactive protein are potential predictive markers of response to infliximab in hidradenitis suppurativa. J Am Acad Dermatol. 2017;76:156–158.
   PubMed Web of Science ®Google Scholar
• van der Zee HH, de Ruiter L, van den Broecke DG, et al. Elevated levels of tumour necrosis factor (TNF)-alpha, interleukin (IL)-1beta and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-alpha and IL-1beta. Br J Dermatol. 2011;164:1292–1298.
   PubMed Web of Science ®Google Scholar
• Giatrakos S, Huse K, Kanni T, et al. Haplotypes of IL-12Rbeta1 impact on the clinical phenotype of hidradenitis suppurativa. Cytokine. 2013;62:297–301.
   PubMed Web of Science ®Google Scholar
• Schlapbach C, Hanni T, Yawalkar N, et al. Expression of the IL-23/Th17 pathway in lesions of hidradenitis suppurativa. J Am Acad Dermatol. 2011;65:790–798.
   PubMed Web of Science ®Google Scholar
• Kurayev A, Ashkar H, Saraiya A, et al. Hidradenitis Suppurativa: review of the pathogenesis and treatment. J Drugs Dermatol. 2016;15:1017–1022.
   PubMed Web of Science ®Google Scholar
• Shah A, Alhusayen R, Amini-Nik S. The critical role of macrophages in the pathogenesis of hidradenitis suppurativa. Inflamm Res. 2017.
   PubMed Web of Science ®Google Scholar
• Di Caprio R, Balato A, Caiazzo G, et al. IL-36 cytokines are increased in acne and hidradenitis suppurativa. Arch Dermatol Res. 2017.
   PubMed Web of Science ®Google Scholar
• Hoffman LK, Ghias MH, Lowes MA. Pathophysiology of hidradenitis suppurativa. Semin Cutan Med Surg. 2017;36:47–54.
   PubMed Web of Science ®Google Scholar
• Deckers IE, van der Zee HH, Boer J, et al. Correlation of early-onset hidradenitis suppurativa with stronger genetic susceptibility and more widespread involvement. J Am Acad Dermatol. 2015;72:485–488.
   PubMed Web of Science ®Google Scholar
• Pink AE, Simpson MA, Desai N, et al. Mutations in the gamma-secretase genes NCSTN, PSENEN, and PSEN1 underlie rare forms of hidradenitis suppurativa (acne inversa). J Invest Dermatol. 2012;132:2459–2461.
   PubMed Web of Science ®Google Scholar
• Fitzsimmons JS, Guilbert PR, Fitzsimmons EM. Evidence of genetic factors in hidradenitis suppurativa. Br J Dermatol. 1985;113:1–8.
   PubMed Web of Science ®Google Scholar
• Ingram JR. The genetics of Hidradenitis Suppurativa. Dermatol Clin. 2016;34:23–28.
   PubMed Web of Science ®Google Scholar
• Melnik BC, Plewig G. Signalling in hidradenitis suppurativa: an approach to pathogenesis by evidence from translational biology. Exp Dermatol. 2013;22:172–177.
   PubMed Web of Science ®Google Scholar
• Zhang X, Sisodia SS. Acne inversa caused by missense mutations in NCSTN is not fully compatible with impairments in Notch signaling. J Invest Dermatol. 2015;135:618–620.
   PubMed Web of Science ®Google Scholar
• Kimball AB, Jemec GB, Yang M, et al. Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment. Br J Dermatol. 2014;171:1434–1442.
   PubMed Web of Science ®Google Scholar
• Kimball AB, Kerdel F, Adams D, et al. Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial. Ann Intern Med. 2012;157:846–855.
   PubMed Web of Science ®Google Scholar
• Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)–a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210–216.
   PubMed Web of Science ®Google Scholar
• Sartorius K, Lapins J, Emtestam L, et al. Suggestions for uniform outcome variables when reporting treatment effects in hidradenitis suppurativa. Br J Dermatol. 2003;149:211–213.
   PubMed Web of Science ®Google Scholar
• Garrone P, Djossou O, Fossiez F, et al. Generation and characterization of a human monoclonal autoantibody that acts as a high affinity interleukin-1 alpha specific inhibitor. Mol Immunol. 1996;33:649–658.
   PubMed Web of Science ®Google Scholar
• Hong DS, Hui D, Bruera E, et al. MABp1, a first-in-class true human antibody targeting interleukin-1alpha in refractory cancers: an open-label, phase 1 dose-escalation and expansion study. Lancet Oncol. 2014;15:656–666.
   PubMed Web of Science ®Google Scholar
• Coleman KM, Gudjonsson JE, Stecher M. Open-label trial of MABp1, a true human monoclonal antibody targeting interleukin 1alpha, for the treatment of psoriasis. JAMA Dermatol. 2015;151:555–556.
   PubMed Web of Science ®Google Scholar
• Carrasco D, Stecher M, Lefebvre GC, et al. An open label, phase 2 study of MABp1 monotherapy for the treatment of acne vulgaris and psychiatric comorbidity. J Drugs Dermatol. 2015;14:560–564.
   PubMed Web of Science ®Google Scholar
• Timper K, Seelig E, Tsakiris DA, et al. Safety, pharmacokinetics, and preliminary efficacy of a specific anti-IL-1alpha therapeutic antibody (MABp1) in patients with type 2 diabetes mellitus. J Diabetes Complications. 2015;29:955–960.
   PubMed Web of Science ®Google Scholar
• Di Paolo NC, Shayakhmetov DM. Interleukin 1alpha and the inflammatory process. Nat Immunol. 2016;17:906–913.
   PubMed Web of Science ®Google Scholar
• Fettelschoss A, Kistowska M, LeibundGut-Landmann S, et al. Inflammasome activation and IL-1beta target IL-1alpha for secretion as opposed to surface expression. Proc Natl Acad Sci USA. 2011;108:18055–18060.
   PubMed Web of Science ®Google Scholar
• Bergsbaken T, Fink SL, Cookson BT. Pyroptosis: host cell death and inflammation. Nat Rev Microbiol. 2009;7:99–109.
   PubMed Web of Science ®Google Scholar
• Lukens JR, Vogel P, Johnson GR, et al. RIP1-driven autoinflammation targets IL-1alpha independently of inflammasomes and RIP3. Nature. 2013;498:224–227.
   PubMed Web of Science ®Google Scholar
• Tzanetakou V, Kanni T, Giatrakou S, et al. Safety and efficacy of anakinra in severe Hidradenitis Suppurativa: a randomized clinical trial. JAMA Dermatol. 2016;152:52–59.
   PubMed Web of Science ®Google Scholar
• Leslie KS, Tripathi SV, Nguyen TV, et al. An open-label study of anakinra for the treatment of moderate to severe hidradenitis suppurativa. J Am Acad Dermatol. 2014;70:243–251.
   PubMed Web of Science ®Google Scholar
• Menis D, Maronas-Jimenez L, Delgado-Marquez AM, et al. Two cases of severe hidradenitis suppurativa with failure of anakinra therapy. Br J Dermatol. 2015;172:810–811.
   PubMed Web of Science ®Google Scholar
• Zarchi K, Dufour DN, Jemec GB. Successful treatment of severe hidradenitis suppurativa with anakinra. JAMA Dermatol. 2013;149:1192–1194.
   PubMed Web of Science ®Google Scholar
• Russo V, Alikhan A. Failure of anakinra in a case of severe Hidradenitis Suppurativa. J Drugs Dermatol. 2016;15:772–774.
   PubMed Web of Science ®Google Scholar
• Cohen I, Rider P, Carmi Y, et al. Differential release of chromatin-bound IL-1alpha discriminates between necrotic and apoptotic cell death by the ability to induce sterile inflammation. Proc Natl Acad Sci USA. 2010;107:2574–2579.
   PubMed Web of Science ®Google Scholar
• GlobeNewswire. [cited 2017 Nov 02]. https://globenewswire.com/news-release/2017/09/07/1113963/0/en/XBiotech-Announces-Presentation-of-Phase-2-Study-Data-Evaluating-MABp1-for-the-Treatment-of-Hidradenitis-Suppurativa.html
   Google Scholar
• Clinicaltrials.gov. [cited 2017 Jun 23]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT01838499?cond=Hidradenitis+Suppurativa&draw=3&rank=29&sect=X01256#all
   Google Scholar
• Clinicaltrials.gov. [cited 2017 Jun 23]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT01448850?term=MEDI8968&rank=1&sect=X70156
   Google Scholar
• Bissonnette R, Luger T, Thaci D, et al. Secukinumab sustains good efficacy and favourable safety in moderate to severe psoriasis up to 3 years of treatment: results from a double-blind extension study. Br J Dermatol. 2017;177(4):1033–1042.
   Google Scholar
• Reich K, Blauvelt A, Armstrong A, et al. Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2017;176:752–758.
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Papp K, Kircik L. Secukinumab: review of clinical evidence from the pivotal studies ERASURE, FIXTURE, and CLEAR. J Clin Aesthet Dermatol. 2016;9:S7–S12.
   PubMedGoogle Scholar
• clinicaltrials.gov. [cited 2017 Jun 26]. Available from: https://clinicaltrials.gov/ct2/results?cond=&term=CJM112&cntry1=&state1=&SearchAll=Search+all+studies&recrs=
   Google Scholar
• Balato A, Scala E, Balato N, et al. Biologics that inhibit the Th17 pathway and related cytokines to treat inflammatory disorders. Expert Opin Biol Ther. 2017;17:1363–1374.
   PubMed Web of Science ®Google Scholar
• Ghoreschi K, Laurence A, Yang XP, et al. Generation of pathogenic T(H)17 cells in the absence of TGF-beta signalling. Nature. 2010;467:967–971.
   PubMed Web of Science ®Google Scholar
• Adami S, Cavani A, Rossi F, et al. The role of interleukin-17A in psoriatic disease. BioDrugs. 2014;28:487–497.
   PubMed Web of Science ®Google Scholar
• Girolomoni G, Mrowietz U, Paul C. Psoriasis: rationale for targeting interleukin-17. Br J Dermatol. 2012;167:717–724.
   PubMed Web of Science ®Google Scholar
• Ogura H, Murakami M, Okuyama Y, et al. Interleukin-17 promotes autoimmunity by triggering a positive-feedback loop via interleukin-6 induction. Immunity. 2008;29:628–636.
   PubMed Web of Science ®Google Scholar
• Kolls JK, McCray PB Jr., Chan YR. Cytokine-mediated regulation of antimicrobial proteins. Nat Rev Immunol. 2008;8:829–835.
   PubMed Web of Science ®Google Scholar
• Shalom-Barak T, Quach J, Lotz M. Interleukin-17-induced gene expression in articular chondrocytes is associated with activation of mitogen-activated protein kinases and NF-kappaB. J Biol Chem. 1998;273:27467–27473.
   PubMed Web of Science ®Google Scholar
• Koenders MI, Kolls JK, Oppers-Walgreen B, et al. Interleukin-17 receptor deficiency results in impaired synovial expression of interleukin-1 and matrix metalloproteinases 3, 9, and 13 and prevents cartilage destruction during chronic reactivated streptococcal cell wall-induced arthritis. Arthritis Rheum. 2005;52:3239–3247.
   PubMed Web of Science ®Google Scholar
• Saunte DM, Mrowietz U, Puig L, et al. Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management. Br J Dermatol. 2017;177(1):47–62.
   Web of Science ®Google Scholar
• Wolk K, Warszawska K, Hoeflich C, et al. Deficiency of IL-22 contributes to a chronic inflammatory disease: pathogenetic mechanisms in acne inversa. J Immunol. 2011;186:1228–1239.
   PubMed Web of Science ®Google Scholar
• Matusiak L, Szczech J, Bieniek A, et al. Increased interleukin (IL)-17 serum levels in patients with hidradenitis suppurativa: implications for treatment with anti-IL-17 agents. J Am Acad Dermatol. 2017;76:670–675.
   PubMed Web of Science ®Google Scholar
• Thorlacius L, Theut Riis P, Jemec GBE. Severe hidradenitis suppurativa responding to treatment with secukinumab: a case report. Br J Dermatol. 2017.  doi: 10.1111/bjd.15769. [Epub ahead of print].
   Google Scholar
• Haber SL, Hamilton S, Bank M, et al. Apremilast: a novel drug for treatment of psoriasis and psoriatic arthritis. Ann Pharmacother. 2016;50:282–290.
   PubMed Web of Science ®Google Scholar
• Torres T, Puig L. Apremilast: a novel oral treatment for psoriasis and psoriatic arthritis. Am J Clin Dermatol. 2017.
   Web of Science ®Google Scholar
• Weber P, Seyed Jafari SM, Yawalkar N, et al. Apremilast in the treatment of moderate to severe hidradenitis suppurativa: a case series of 9 patients. J Am Acad Dermatol. 2017;76:1189–1191.
   PubMed Web of Science ®Google Scholar
• Guo RF, Ward PA. Role of C5a in inflammatory responses. Annu Rev Immunol. 2005;23:821–852.
   PubMed Web of Science ®Google Scholar
• Marik PE, Taeb AM. SIRS, qSOFA and new sepsis definition. J Thorac Dis. 2017;9:943–945.
   PubMed Web of Science ®Google Scholar
• Guo RF, Ward PA. C5a, a therapeutic target in sepsis. Recent Pat Antiinfect Drug Discov. 2006;1:57–65.
   PubMedGoogle Scholar
• Pernicova I, Korbonits M. Metformin–mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol. 2014;10:143–156.
   PubMed Web of Science ®Google Scholar
• Saisho Y. Metformin and inflammation: its potential beyond glucose-lowering effect. Endocr Metab Immune Disord Drug Targets. 2015;15:196–205.
   PubMed Web of Science ®Google Scholar
• Fitzgerald DC, Meade KG, McEvoy AN, et al. Tumour necrosis factor-alpha (TNF-alpha) increases nuclear factor kappaB (NFkappaB) activity in and interleukin-8 (IL-8) release from bovine mammary epithelial cells. Vet Immunol Immunopathol. 2007;116:59–68.
   PubMed Web of Science ®Google Scholar
• Renard P, Zachary MD, Bougelet C, et al. Effects of antioxidant enzyme modulations on interleukin-1-induced nuclear factor kappa B activation. Biochem Pharmacol. 1997;53:149–160.
   PubMed Web of Science ®Google Scholar
• Arun B, Loffeld A. Long-standing hidradenitis suppurativa treated effectively with metformin. Clin Exp Dermatol. 2009;34:920–921.
   PubMed Web of Science ®Google Scholar
• Verdolini R, Clayton N, Smith A, et al. Metformin for the treatment of hidradenitis suppurativa: a little help along the way. J Eur Acad Dermatol Venereol. 2013;27:1101–1108.
   PubMed Web of Science ®Google Scholar
• Montecucco C, Molgo J. Botulinal neurotoxins: revival of an old killer. Curr Opin Pharmacol. 2005;5:274–279.
   PubMed Web of Science ®Google Scholar
• Khoo AB, Burova EP. Hidradenitis suppurativa treated with Clostridium botulinum toxin A. Clin Exp Dermatol. 2014;39:749–750.
   PubMed Web of Science ®Google Scholar
• Feito-Rodriguez M, Sendagorta-Cudos E, Herranz-Pinto P, et al. Prepubertal hidradenitis suppurativa successfully treated with botulinum toxin A. Dermatologic Surgery. 2009;35:1300–1302.
   PubMed Web of Science ®Google Scholar
• O’Reilly DJ, Pleat JM, Richards AM. Treatment of hidradenitis suppurativa with botulinum toxin A. Plast Reconstr Surg. 2005;116:1575–1576.
   PubMed Web of Science ®Google Scholar
• Microdermis.com. [cited 2017 Jun 29]. Available from: http://www.microdermis.com/provodine.html
   Google Scholar
• Riis PT, Boer J, Prens EP, et al. Intralesional triamcinolone for flares of hidradenitis suppurativa (HS): a case series. J Am Acad Dermatol. 2016;75:1151–1155.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. PubChem bioassay database; CID 31307 NCI. [cited 2016 Apr 05]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/triamcinolone#section=Top
   Google Scholar
• Kimball AB, Okun MM, Williams DA, et al. Two phase 3 trials of adalimumab for Hidradenitis Suppurativa. N Engl J Med. 2016;375:422–434.
   PubMed Web of Science ®Google Scholar
• Martorell A, Romani J, Bassas J, et al. Effectiveness and safety of adalimumab in hidradenitis suppurativa: evidence from Spanish real-world data. Exp Dermatol. 2017;26:24.
   PubMedGoogle Scholar
• Gulliver W, Okun MM, Martorell A, et al. Therapeutic response guided dosing strategy to optimize long-term adalimumab treatment in patients with hidradenitis suppurativa: integrated results from the PIONEER phase 3 trials. J Investigative Dermatol. 2016;136:S161–S.
   PubMed Web of Science ®Google Scholar
• Jemec G, Gottlieb A, Forman S, et al. Efficacy and safety of adalimumab in patients with moderate to severe hidradenitis suppurativa: results from PIONEER II, a phase 3, randomized, placebo-controlled trial. J Am Acad Dermatol. 2015;72:Ab45–Ab.
   Web of Science ®Google Scholar
• Blok JL, Li K, Brodmerkel C, et al. Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum. Br J Dermatol. 2016;174:839–846.
   PubMed Web of Science ®Google Scholar
• van der Zee HH, Prens EP. Failure of anti-interleukin-1 therapy in severe hidradenitis suppurativa: a case report. Dermatology. 2013;226:97–100.
   PubMed Web of Science ®Google Scholar
• Jaeger T, Andres C, Grosber M, et al. Pyoderma gangrenosum and concomitant hidradenitis suppurativa–rapid response to canakinumab (anti-IL-1beta). Eur J Dermatol. 2013;23:408–410.
   PubMed Web of Science ®Google Scholar
• Houriet C, Seyed Jafari SM, Thomi R, et al. Canakinumab for severe Hidradenitis Suppurativa: preliminary experience in 2 cases. JAMA Dermatol. 2017;153(11):1195-1197.
   Web of Science ®Google Scholar
• Thorlacius L, Ingram JR, Garg A, et al. Protocol for the development of a core domain set for hidradenitis suppurativa trial outcomes. BMJ Open. 2017;7:e014733.
   PubMed Web of Science ®Google Scholar